A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

Completed · Phase 4

Conditions studied: Rheumatoid Arthritis

In brief

This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.

Key facts

Study ID

NCT01163747

Run by

Genentech, Inc.

People needed

91

Starts

2010-09-01

Expected to finish

2012-06-01

Last updated by the study team

2012-12-07

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients, ≥ 18 to < 65 years of age
• Rheumatoid Arthritis (RA) of > 6 months duration at baseline (American College of Rheumatology criteria)
• Willing to receive immunization with pneumococcal polysaccharide and tetanus toxoid adsorbed vaccines
• Previous immunization with pneumococcal polysaccharide must have occurred ≥ 3 years of baseline, with tetanus containing vaccine ≥ 5 years
• Methotrexate therapy for at least 8 weeks prior to baseline at stable dose of 7.5-25 mg/week (oral or parenteral)
• Other disease-modifying antirheumatic drugs (DMARDs) must be withdrawn before baseline
• Oral corticosteroids must be at stable dose of < 10 mg/day prednisone or equivalent
• Body weight ≤ 150 kg at screening

You may not qualify if…

• Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 8 weeks after baseline
• History of or current inflammatory joint disease or rheumatic autoimmune disease other than RA
• Pre-existing central nervous system demyelinating or seizure disorders
• Active current or history of recurrent bacterial, viral fungal, mycobacterial and other infections
• Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to baseline or oral antibiotics within 2 weeks prior to baseline
• Active tuberculosis requiring treatment within 3 years prior to baseline
• Primary or secondary immunodeficiency (history or currently active)
• Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline
• Previous treatment with RoActemra/Actemra

Where it is running

• Study site — Anniston, Alabama, United States
• Study site — Birmingham, Alabama, United States
• Study site — Huntsville, Alabama, United States
• Study site — Glendale, Arizona, United States
• Study site — Mesa, Arizona, United States
• Study site — Paradise Valley, Arizona, United States
• Study site — Paradise Valley, Arizona, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Jonesboro, Arkansas, United States
• Study site — Fullerton, California, United States
• Study site — Hemet, California, United States
• Study site — San Leandro, California, United States
• Study site — Santa Maria, California, United States
• Study site — Upland, California, United States
• Study site — Bridgeport, Connecticut, United States
• Study site — Melbourne, Florida, United States
• Study site — South Miami, Florida, United States
• Study site — Tavares, Florida, United States
• Study site — Boise, Idaho, United States
• Study site — Idaho Falls, Idaho, United States
• Study site — Maywood, Illinois, United States
• Study site — Vernon Hills, Illinois, United States
• Study site — South Bend, Indiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.